Related Experiment Video
Updated: Jun 24, 2026
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Identification of Potential Inhibitors Targeting Non-Structural Proteins NS3 and NS5 of Dengue Virus Using Docking
Alomgir Hossain1,2, Faria Tasnin Joti1, Md Shohag Hossain1
1Computational Biosciences and Chemistry Research Organization, Rajshahi 6205, Bangladesh.
Abstract:
Background: Dengue virus (DENV) is the fatal pathogenic arthropod-borne virus (arboviruses) that belongs to the Flaviviridae family, which transmits to humans through mosquito bites from infected Aedes aegypti and Aedes albopictus mosquitoes or maternal-fetal transmission. Despite antigenic differences, the four serotypes of DENV (DENV-1 to DENV-4) share 65-78% of their genome. Non-structural (NS) proteins amongst serotypes show analogous functions. Among NS proteins, NS3 and NS5 are frequently used as targets for antiviral drugs due to their multifunctional roles. Methods: To identify potential inhibitors of DENV, we created a phytochemical library of 898 compounds derived from 17 medicinal plants recognized for their medicinal and antiviral properties. The phytochemicals library has been docked against the target proteins. Phytochemicals with a docking score greater than -8.0 kcal/mol were selected for further evaluation using a machine learning approach. Further, molecular dynamics (MD) simulations were conducted to evaluate the root mean square deviation, root mean square fluctuation, solvent-accessible surface area, radius of gyration, and hydrogen bond count of the compounds. Results: From the docking results, Silibinin, Rubiadin, and Ellagic acid showed binding affinities of -8.5, -8.3, and -8.2 kcal/mol, respectively, for NS3, and NSC 640467, Bisandrographolide A, and Andrographidin A showed binding affinities of -9.3, -10.1, and -9.3 kcal/mol, respectively, for NS5 target proteins. These compounds exhibited strong interactions with target proteins. MD simulation results confirmed the stable formation of protein-ligand complexes. Further, absorption, distribution, metabolism, excretion, and toxicity (ADMET) and bioactivity predictions confirmed their pharmacological safety. Conclusions: Despite global public health concerns, DENV still lacks specific drug treatments. Our identified new drug candidates might help for developing effective antiviral inhibitors against the DENV. However, further confirmation is needed through in vivo and in vitro research.
Insights
Researchers screened 898 phytochemicals against Dengue virus (DENV) targets, identifying potent natural compounds like Silibinin and NSC 640467. These promising drug candidates show potential for developing new antiviral therapies against DENV infections.
Area of Science:
- Virology
- Medicinal Chemistry
- Computational Biology
Background:
- Dengue virus (DENV), a significant arbovirus from the Flaviviridae family, poses a global health threat.
- DENV serotypes share genomic similarities, with non-structural proteins NS3 and NS5 being key targets for antiviral drug development.
- Current treatments for DENV are limited, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To identify novel phytochemical inhibitors against Dengue virus (DENV) non-structural proteins (NS3 and NS5).
- To evaluate the binding affinity and stability of selected phytochemicals using computational methods.
- To assess the pharmacological safety of potential DENV inhibitors.
Main Methods:
- A phytochemical library of 898 compounds from medicinal plants was screened using molecular docking against DENV NS3 and NS5 proteins.
- Compounds with docking scores > -8.0 kcal/mol were further analyzed using machine learning and molecular dynamics (MD) simulations.
- Absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions were performed to assess pharmacological safety.
Main Results:
- Silibinin, Rubiadin, and Ellagic acid showed strong binding affinities for DENV NS3 (-8.5, -8.3, -8.2 kcal/mol).
- NSC 640467, Bisandrographolide A, and Andrographidin A demonstrated high binding affinities for DENV NS5 (-9.3, -10.1, -9.3 kcal/mol).
- MD simulations confirmed stable protein-ligand complexes, and ADMET predictions indicated pharmacological safety.
Conclusions:
- The study identified several potent natural compounds as potential drug candidates for Dengue virus (DENV) infection.
- These compounds, including Silibinin and NSC 640467, show promise for developing effective antiviral inhibitors against DENV.
- Further in vitro and in vivo studies are required to validate these findings and advance potential DENV therapeutics.
